Amarin Corp Plcuk (AMRN) Cash & Current Investments (2010 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Cash & Current Investments of $314.7 million for Q2 2026, up 5.35% year-over-year from $298.7 million in Q2 2025, and up 2.21% quarter-over-quarter from $307.9 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Cash & Current Investments (2010 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Cash & Current Investments for 17 consecutive years, with $314.7 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash & Current Investments rose 5.35% year-over-year to $314.7 million; the TTM figure through Jun 2026 stood at $314.7 million (up 5.35% YoY), while the FY2025 annual figure was $302.6 million, up 2.84% from the prior year.
- Cash & Current Investments improved to $314.7 million in Q2 2026 per AMRN's latest filing, from $307.9 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $362.6 million in Q1 2022 and bottomed at $281.8 million in Q1 2025.
- Historically, Cash & Current Investments has averaged $308.6 million across 5 years, with a median of $307.3 million in 2024.
- Annual changes were most pronounced in 2022 — Cash & Current Investments slumped 38.45% — and 2026, when it gained 9.25%.
- Amarin Corp Plc\Uk's Cash & Current Investments stood at $309.4 million in 2022, then climbed by 3.65% to $320.7 million in 2023, then slipped by 8.25% to $294.2 million in 2024, then gained by 2.84% to $302.6 million in 2025, then gained by 4.0% to $314.7 million in 2026.
- Business Quant data shows AMRN's Cash & Current Investments at $314.7 million in Q2 2026, $307.9 million in Q1 2026, and $302.6 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 20.76 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 6.57 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 7.14 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 7.69 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 4.90 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 13.99 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.18 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 11.70 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 4.17 Bn |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | 314.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 314.70 Mn |
| Mar 31, 2026 | 307.90 Mn |
| Dec 31, 2025 | 302.59 Mn |
| Sep 30, 2025 | 286.60 Mn |
| Jun 30, 2025 | 298.73 Mn |
| Mar 31, 2025 | 281.82 Mn |
| Dec 31, 2024 | 294.22 Mn |
| Sep 30, 2024 | 305.74 Mn |
| Jun 30, 2024 | 306.66 Mn |
| Mar 31, 2024 | 308.18 Mn |
| Dec 31, 2023 | 320.66 Mn |
| Sep 30, 2023 | 320.66 Mn |
| Jun 30, 2023 | 312.92 Mn |
| Mar 31, 2023 | 304.41 Mn |
| Dec 31, 2022 | 309.36 Mn |
| Sep 30, 2022 | 303.70 Mn |
| Jun 30, 2022 | 313.23 Mn |
| Mar 31, 2022 | 362.61 Mn |
| Dec 31, 2021 | 454.13 Mn |
| Sep 30, 2021 | 479.20 Mn |